{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:49:53Z","timestamp":1790660993060,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["Bright Red Mission Award"],"award-info":[{"award-number":["Bright Red Mission Award"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Government of Nova Scotia","award":["Graduate Scholarship"],"award-info":[{"award-number":["Graduate Scholarship"]}]},{"DOI":"10.13039\/501100004073","name":"Killam Trusts","doi-asserted-by":"publisher","award":["Doctoral Award"],"award-info":[{"award-number":["Doctoral Award"]}],"id":[{"id":"10.13039\/501100004073","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Doctoral Award"],"award-info":[{"award-number":["Doctoral Award"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT173471"],"award-info":[{"award-number":["PJT173471"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK057136"],"award-info":[{"award-number":["DK057136"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the ACCORD study, participants with the haptoglobin (Hp) 2\u20132 phenotype and glycated hemoglobin (HbA<jats:sub>1c<\/jats:sub>)\u2009\u2265\u20098.0% had a higher risk of coronary artery disease (CAD) compared to those with HbA<jats:sub>1c<\/jats:sub> 7.0\u20137.9%. However, this association was not observed in participants without the Hp2-2 phenotype. The optimal glycemic target for CAD prevention for the Hp phenotypes remains uncertain and may vary based on demographic and clinical factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate how reaching clinically relevant HbA<jats:sub>1c<\/jats:sub> targets relates to the risk of CAD in different Hp phenotype groups among a diverse cohort of individuals with T2DM (the Look AHEAD study, HbA<jats:sub>1c<\/jats:sub>\u2009\u2264\u200911% at baseline).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cox regression models with time-varying covariables were used to quantify the association between time-varying achieved HbA<jats:sub>1c<\/jats:sub> (&lt;\u20096.5%, 6.5\u20136.9%, and \u2265\u20098.0% compared to 7.0-7.9%), updated at years 1\u20134, 6, 8, and 10, and incident CAD in the Hp2-2 (<jats:italic>n<\/jats:italic>\u2009=\u20091,587) and non-Hp2-2 (<jats:italic>n<\/jats:italic>\u2009=\u20092,944) phenotypes separately. Further pre-specified subgroup analyses by age, sex, history of cardiovascular disease (CVD), race, and diabetes duration were performed in each Hp phenotype group separately.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with HbA<jats:sub>1c<\/jats:sub> 7.0-7.9%, having HbA<jats:sub>1c<\/jats:sub>\u2009&lt;\u20096.5% was associated with a 29% lower CAD risk among participants with the non-Hp2-2 phenotype (adjusted HR 0.71, 95% CI 0.55\u20130.90). In subgroup analyses, this association was present in participants with the non-Hp2-2 phenotype who were male (0.60, 0.44\u20130.83), who did not have a history of CVD (0.65, 0.47\u20130.90), who were aged\u2009\u2265\u200965 years (0.64, 0.44\u20130.94), who were White (0.68, 0.51\u20130.91), or who had diabetes duration\u2009&gt;\u200910 years (0.58, 0.35\u20130.95). HbA<jats:sub>1c<\/jats:sub>\u2009\u2265\u20098.0% was associated with CAD risk only among participants with the Hp2-2 phenotype who had a history of CVD (1.79, 1.00-3.20). No associations were found between the other HbA<jats:sub>1c<\/jats:sub> targets and CAD risk when participants with the Hp2-2 phenotype were grouped together or divided into subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The differences in our results compared to our previous findings may be due to variations in the study populations and factors associated with weight loss, making it difficult to draw definitive conclusions. Our current findings should be considered in the context of hypothesis generation, and ideally, will encourage additional research in this field.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-024-02448-z","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T17:02:32Z","timestamp":1728493352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The relationship between repeated measurements of HbA1c and risk of coronary events among the common haptoglobin phenotype groups: the Action for Health in Diabetes (Look AHEAD) study"],"prefix":"10.1186","volume":"23","author":[{"given":"A. S.","family":"Carew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Bancks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Espeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Bahnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. L.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. P.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Sapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Urquhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. B.","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. E.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"2448_CR1","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP, Goff DC Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr., Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"2448_CR2","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"2448_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129\u201339.","journal-title":"N Engl J Med"},{"key":"2448_CR4","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa1204942","volume":"367","author":"S Finfer","year":"2012","unstructured":"Finfer S, Liu B, Chittock DR, Norton R, Myburgh JA, McArthur C, Mitchell I, Foster D, Dhingra V, Henderson WR, Ronco JJ, Bellomo R, Cook D, McDonald E, Dodek P, H\u00e9bert PC, Heyland DK, Robinson BG. Hypoglycemia and risk of death in critically ill patients. N Engl J Med. 2012;367:1108\u201318.","journal-title":"N Engl J Med"},{"key":"2448_CR5","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","volume":"363","author":"S Zoungas","year":"2010","unstructured":"Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410\u20138.","journal-title":"N Engl J Med"},{"key":"2448_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-018-0875-1","volume":"16","author":"D Orozco-Beltr\u00e1n","year":"2018","unstructured":"Orozco-Beltr\u00e1n D, Artola S, Jans\u00e0 M, Lopez de la Torre-Casares M, Fuster E. Impact of hypoglycemic episodes on health-related quality of life of type-2 diabetes mellitus patients: development and validation of a specific QoLHYPO\u00a9 questionnaire. Health Qual Life Outcomes. 2018;16:1\u201313.","journal-title":"Health Qual Life Outcomes"},{"key":"2448_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3111\/13696998.2011.610852","volume":"14","author":"C Fidler","year":"2011","unstructured":"Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14:646\u201355.","journal-title":"J Med Econ"},{"key":"2448_CR8","doi-asserted-by":"publisher","first-page":"l5887","DOI":"10.1136\/bmj.l5887","volume":"367","author":"R Rodriguez-Gutierrez","year":"2019","unstructured":"Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zu\u00f1iga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ. 2019;367:l5887.","journal-title":"BMJ"},{"key":"2448_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2015;38:140\u20139.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2448_CR10","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.jcjd.2017.10.030","volume":"42","author":"SA Imran","year":"2018","unstructured":"Imran SA, Agarwal G, Bajaj HS, Ross S. Targets for glycemic control. Can J Diabetes. 2018;42(Suppl 1):S42\u20136.","journal-title":"Can J Diabetes"},{"key":"2448_CR11","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753\u201386.","journal-title":"Diabetes Care"},{"key":"2448_CR12","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.jcjd.2017.10.030","volume":"42","author":"SA Imran","year":"2018","unstructured":"Imran SA, Agarwal G, Bajaj HS, Ross S. Targets for glycemic control. Can J Diabetes. 2018;42:S42\u20136.","journal-title":"Can J Diabetes"},{"key":"2448_CR13","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022;65:1925\u20131966.","DOI":"10.1007\/s00125-022-05787-2"},{"key":"2448_CR14","doi-asserted-by":"crossref","unstructured":"Cahill LE, Warren RA, Carew AS, Levy AP, Ginsberg HN, Sapp J, Lache O, Rimm EB. The relationship between time-varying achieved HbA1c and risk of coronary events depends on haptoglobin phenotype among white and black ACCORD participants. Diabetes Care. 2023:dc230760.","DOI":"10.2337\/figshare.23925750"},{"key":"2448_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jacc.2019.11.051","volume":"75","author":"AS Carew","year":"2020","unstructured":"Carew AS, Levy AP, Ginsberg HN, Coca S, Lache O, Ransom T, Byington R, Rimm EB, Sapp J, Gardner M. Haptoglobin phenotype modifies the influence of intensive glycemic control on cardiovascular outcomes. J Am Coll Cardiol. 2020;75:512\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"2448_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2337\/dc23-2165","volume":"47","author":"LE Cahill","year":"2024","unstructured":"Cahill LE, Warren RA, Carew AS, Levy AP, Sapp J, Samuel M, Selvin E, Lavall\u00e9e SK, Poulter N, Marre M, Harrap S, Mancia G, Harris K, Chalmers J, Woodward M, Rimm EB. Haptoglobin phenotype and intensive glycemic control for coronary artery disease risk reduction in people with type 2 diabetes: the ADVANCE study. Diabetes Care. 2024;47:835\u201343.","journal-title":"Diabetes Care"},{"key":"2448_CR17","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/ATVBAHA.118.312232","volume":"39","author":"R Asleh","year":"2019","unstructured":"Asleh R, Levy AP, Levy NS, Asleh A, Goldenstein H, Segol I, Gulati R, Lerman LO, Lerman A. Haptoglobin phenotype is associated with high-density lipoprotein-bound hemoglobin content and coronary endothelial dysfunction in patients with mild nonobstructive coronary artery disease. Arterioscler Thromb Vasc Biol. 2019;39:774\u201386.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2448_CR18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jacc.2012.09.063","volume":"61","author":"LE Cahill","year":"2013","unstructured":"Cahill LE, Levy AP, Chiuve SE, Jensen MK, Wang H, Shara NM, Blum S, Howard BV, Pai JK, Mukamal KJ, Rexrode KM, Rimm EB. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol. 2013;61:728\u201337.","journal-title":"J Am Coll Cardiol"},{"key":"2448_CR19","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/j.jacc.2015.07.076","volume":"66","author":"LE Cahill","year":"2015","unstructured":"Cahill LE, Jensen MK, Chiuve SE, Shalom H, Pai JK, Flint AJ, Mukamal KJ, Rexrode KM, Levy AP, Rimm EB. The risk of coronary heart disease associated with glycosylated hemoglobin of 6.5% or greater is pronounced in the haptoglobin 2\u20132 genotype. J Am Coll Cardiol. 2015;66:1791\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"2448_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1751-553X.2007.00898.x","volume":"29","author":"K Carter","year":"2007","unstructured":"Carter K, Worwood M. Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int J Lab Hematol. 2007;29:92\u2013110.","journal-title":"Int J Lab Hematol"},{"key":"2448_CR21","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1161\/01.RES.0000076889.23082.F1","volume":"92","author":"R Asleh","year":"2003","unstructured":"Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circul Res. 2003;92:1193\u2013200.","journal-title":"Circul Res"},{"key":"2448_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"LAR Group","year":"2013","unstructured":"Group LAR. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145\u201354.","journal-title":"N Engl J Med"},{"key":"2448_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12933-024-02164-8","volume":"23","author":"RA Warren","year":"2024","unstructured":"Warren RA, Bancks MP, Carew AS, Levy AP, Sapp J, Bahnson J, Lewis CE, Rimm EB, Espeland MA, Cahill LE. Intensive lifestyle intervention in type 2 diabetes and risk of incident coronary artery disease for the common haptoglobin phenotypes: the look AHEAD study. Cardiovasc Diabetol. 2024;23:82.","journal-title":"Cardiovasc Diabetol"},{"key":"2448_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0197-2456(03)00064-3","volume":"24","author":"LAR Group","year":"2003","unstructured":"Group LAR, Look AHEAD. (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24:610\u201328.","journal-title":"Control Clin Trials"},{"key":"2448_CR25","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1515\/cclm-2013-0018","volume":"51","author":"NS Levy","year":"2013","unstructured":"Levy NS, Vardi M, Blum S, Miller-Lotan R, Afinbinder Y, Cleary PA, Paterson AD, Bharaj B, Snell-Bergeon JK, Rewers MJ, Lache O, Levy AP. An enzyme linked immunosorbent assay (ELISA) for the determination of the human haptoglobin phenotype. Clin Chem Lab Med. 2013;51:1615\u201322.","journal-title":"Clin Chem Lab Med"},{"key":"2448_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2337\/dc21-1429","volume":"45","author":"RA Warren","year":"2022","unstructured":"Warren RA, Carew AS, Andreou P, Herman C, Levy AP, Ginsberg HN, Sapp J, Rimm EB, Kirkland S, Cahill LE. Haptoglobin phenotype modifies the effect of fenofibrate on risk of coronary event: ACCORD lipid trial. Diabetes Care. 2022;45:241\u201350.","journal-title":"Diabetes Care"},{"key":"2448_CR27","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.2337\/dc23-S006","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME. Isaacs D and Johnson EL. 6. Glycemic targets: standards of care in diabetes\u20142023. Diabetes Care. 2023;46:S97\u2013110.","journal-title":"Diabetes Care"},{"key":"2448_CR28","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.amjcard.2007.03.003","volume":"99","author":"JB Buse","year":"2007","unstructured":"Buse JB, Group AS. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99:S21\u201333.","journal-title":"Am J Cardiol"},{"key":"2448_CR29","doi-asserted-by":"publisher","first-page":"100681","DOI":"10.1016\/j.ajpc.2024.100681","volume":"18","author":"LE Cahill","year":"2024","unstructured":"Cahill LE, Warren RA, Bahn GD, Carew AS, Levy AP, Sapp J, Rimm EB, Reaven P. Haptoglobin phenotype and intensive glycemic control for coronary artery disease risk reduction in people with type two diabetes: the veterans affairs diabetes trial. Am J Prev Cardiol. 2024;18:100681.","journal-title":"Am J Prev Cardiol"},{"key":"2448_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/156720208785425675","volume":"5","author":"J Staals","year":"2008","unstructured":"Staals J, Pieters BM, Knottnerus IL, Rouhl RP, van Oostenbrugge RJ, Delanghe JR, Lodder J. Haptoglobin polymorphism and lacunar stroke. Curr Neurovasc Res. 2008;5:153\u20138.","journal-title":"Curr Neurovasc Res"},{"key":"2448_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1479164114539713","volume":"11","author":"T Costacou","year":"2014","unstructured":"Costacou T, Secrest AM, Ferrell RE, Orchard TJ. Haptoglobin genotype and cerebrovascular disease incidence in type 1 diabetes. Diabetes Vasc Dis Res. 2014;11:335\u201342.","journal-title":"Diabetes Vasc Dis Res"},{"key":"2448_CR32","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1182\/blood.V98.13.3693","volume":"98","author":"M Melamed-Frank","year":"2001","unstructured":"Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, Levy AP. Structure-function analysis of the antioxidant properties of haptoglobin. Blood. 2001;98:3693\u20138.","journal-title":"Blood"},{"key":"2448_CR33","doi-asserted-by":"publisher","first-page":"e000732","DOI":"10.1161\/JAHA.113.000732","volume":"3","author":"R Pechlaner","year":"2014","unstructured":"Pechlaner R, Kiechl S, Willeit P, Demetz E, Haun M, Weger S, Oberhollenzer F, Kronenberg F, Bonora E, Weiss G, Willeit J. Haptoglobin 2\u20132 genotype is not associated with cardiovascular risk in subjects with elevated glycohemoglobin-results from the Bruneck Study. J Am Heart Association. 2014;3:e000732.","journal-title":"J Am Heart Association"},{"key":"2448_CR34","doi-asserted-by":"publisher","first-page":"e000732","DOI":"10.1161\/JAHA.113.000732","volume":"3","author":"R Pechlaner","year":"2014","unstructured":"Pechlaner R, Kiechl S, Willeit P, Demetz E, Haun M, Weger S, Oberhollenzer F, Kronenberg F, Bonora E, Weiss G. Haptoglobin 2-2 genotype is not associated with cardiovascular risk in subjects with elevated glycohemoglobin\u2014results from the bruneck study. J Am Heart Association. 2014;3:e000732.","journal-title":"J Am Heart Association"},{"key":"2448_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12265-012-9361-z","volume":"5","author":"T Costacou","year":"2012","unstructured":"Costacou T, Levy AP. Haptoglobin genotype and its role in diabetic cardiovascular disease. J Cardiovasc Transl Res. 2012;5:423\u201335.","journal-title":"J Cardiovasc Transl Res"},{"key":"2448_CR36","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1210\/clinem\/dgab434","volume":"106","author":"J White","year":"2021","unstructured":"White J, Tannenbaum C, Klinge I, Schiebinger L, Clayton J. The integration of sex and gender considerations into biomedical research: lessons from international funding agencies. J Clin Endocrinol Metabolism. 2021;106:3034\u201348.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2448_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jama.2021.13304","volume":"326","author":"A Flanagin","year":"2021","unstructured":"Flanagin A, Frey T, Christiansen SL, Committee AMoS. Updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA. 2021;326:621\u20137.","journal-title":"JAMA"},{"key":"2448_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis","author":"FE Harrell","year":"2001","unstructured":"Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. London: Springer; 2001."},{"key":"2448_CR39","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1021\/bi0362626","volume":"43","author":"VV Bamm","year":"2004","unstructured":"Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry. 2004;43:3899\u2013906.","journal-title":"Biochemistry"},{"key":"2448_CR40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1161\/01.RES.0000156653.05853.b9","volume":"96","author":"R Asleh","year":"2005","unstructured":"Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circul Res. 2005;96:435\u201341.","journal-title":"Circul Res"},{"key":"2448_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2006.04.032","volume":"191","author":"J Guetta","year":"2007","unstructured":"Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP. Haptoglobin genotype modulates the balance of Th1\/Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis. 2007;191:48\u201353.","journal-title":"Atherosclerosis"},{"key":"2448_CR42","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.2337\/db08-0450","volume":"57","author":"R Asleh","year":"2008","unstructured":"Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, Rock W, Aviram M, Milman U, Shapira C, Abassi Z, Levy AP. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2\u20132 genotype. Diabetes. 2008;57:2794\u2013800.","journal-title":"Diabetes"},{"key":"2448_CR43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.clnu.2019.01.019","volume":"39","author":"KY Tang","year":"2020","unstructured":"Tang KY, Huang SY, Cheng TM, Bai CH, Chang JS. Haptoglobin phenotype influences the effectiveness of diet-induced weight loss in middle-age abdominally obese women with metabolic abnormalities. Clin Nutr. 2020;39:225\u201333.","journal-title":"Clin Nutr"},{"key":"2448_CR44","doi-asserted-by":"publisher","first-page":"6035138","DOI":"10.1155\/2020\/6035138","volume":"2020","author":"R Ricotti","year":"2020","unstructured":"Ricotti R, De Feudis M, Peri C, Corazzari M, Genoni G, Giordano M, Mancioppi V, Agosti E, Bellone S, Prodam F. Haptoglobin phenotypes are associated with the postload glucose and insulin levels in pediatric obesity. Int J Endocrinol. 2020;2020:6035138.","journal-title":"Int J Endocrinol"},{"key":"2448_CR45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1210\/er.2016-1009","volume":"37","author":"M Maffei","year":"2016","unstructured":"Maffei M, Barone I, Scabia G, Santini F. The multifaceted haptoglobin in the context of adipose tissue and metabolism. Endocr Rev. 2016;37:403\u201316.","journal-title":"Endocr Rev"},{"key":"2448_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jclinepi.2003.08.009","volume":"57","author":"ST Brookes","year":"2004","unstructured":"Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol. 2004;57:229\u201336.","journal-title":"J Clin Epidemiol"},{"key":"2448_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(88)92956-X","volume":"2","author":"CJ Bulpitt","year":"1988","unstructured":"Bulpitt CJ. Subgroup analysis. Lancet. 1988;2:31\u20134.","journal-title":"Lancet"},{"key":"2448_CR48","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1093\/genetics\/149.4.2079","volume":"149","author":"J Shoemaker","year":"1998","unstructured":"Shoemaker J, Painter I, Weir B. A bayesian characterization of hardy-Weinberg disequilibrium. Genetics. 1998;149:2079\u201388.","journal-title":"Genetics"},{"key":"2448_CR49","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1046\/j.1365-2540.1998.00360.x","volume":"80","author":"KL Ayres","year":"1998","unstructured":"Ayres KL, Balding DJ. Measuring departures from Hardy\u2013Weinberg: a Markov chain Monte Carlo method for estimating the inbreeding coefficient. Heredity. 1998;80:769\u201377.","journal-title":"Heredity"},{"key":"2448_CR50","first-page":"708","volume":"14","author":"KA Liu","year":"2016","unstructured":"Liu KA, Mager NA. Women\u2019s involvement in clinical trials: historical perspective and future implications. Pharm Pract. 2016;14:708.","journal-title":"Pharm Pract"},{"key":"2448_CR51","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1001\/jamainternmed.2014.4758","volume":"174","author":"MR Sardar","year":"2014","unstructured":"Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Intern Med. 2014;174:1868\u201370.","journal-title":"JAMA Intern Med"},{"key":"2448_CR52","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2337\/dc22-0772","volume":"46","author":"JM Rodriguez-Valadez","year":"2023","unstructured":"Rodriguez-Valadez JM, Tahsin M, Fleischmann KE, Masharani U, Yeboah J, Park M, Li L, Weber E, Li Y, Berkalieva A, Max W, Hunink MGM, Ferket BS. Cardiovascular and renal benefits of novel diabetes drugs by baseline cardiovascular risk: a systematic review, meta-analysis, and meta-regression. Diabetes Care. 2023;46:1300\u201310.","journal-title":"Diabetes Care"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02448-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02448-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02448-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T18:02:31Z","timestamp":1728496951000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02448-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2448"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02448-z","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each participating center obtained ethical approval, and all participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"One of our authors, Dr. Andrew Levy, is the author of a patent owned by his university regarding use of haptoglobin genotype to predict susceptibility to cardiovascular disease in individuals with diabetes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"356"}}